What is Zacks Research's Forecast for SRPT Q2 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Zacks Research raised their Q2 2026 earnings estimates for shares of Sarepta Therapeutics in a research note issued on Tuesday, July 8th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings of $0.71 per share for the quarter, up from their previous forecast of $0.67. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.67 per share. Zacks Research also issued estimates for Sarepta Therapeutics' Q3 2026 earnings at $0.86 EPS, Q4 2026 earnings at $0.81 EPS, FY2026 earnings at $3.03 EPS, Q1 2027 earnings at $0.86 EPS, Q2 2027 earnings at $1.01 EPS and FY2027 earnings at $3.86 EPS.

Several other brokerages have also commented on SRPT. Piper Sandler lowered Sarepta Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $70.00 to $36.00 in a report on Monday, June 16th. Scotiabank upgraded Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 target price on the stock in a research report on Friday, June 6th. Oppenheimer dropped their price target on shares of Sarepta Therapeutics from $123.00 to $45.00 and set an "outperform" rating on the stock in a research note on Friday, June 20th. Needham & Company LLC reduced their price objective on shares of Sarepta Therapeutics from $125.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, June 16th. Finally, Mizuho decreased their price objective on shares of Sarepta Therapeutics from $85.00 to $40.00 and set an "outperform" rating on the stock in a report on Wednesday, June 18th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $58.54.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT traded down $0.90 during trading on Friday, reaching $18.17. 3,075,372 shares of the company's stock traded hands, compared to its average volume of 2,241,596. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics has a fifty-two week low of $16.88 and a fifty-two week high of $154.13. The company has a 50-day simple moving average of $31.89 and a 200-day simple moving average of $72.63. The firm has a market cap of $1.79 billion, a PE ratio of -6.75 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The firm's quarterly revenue was up 80.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.73 EPS.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC increased its position in Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares during the last quarter. Byrne Asset Management LLC purchased a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at approximately $30,000. Center for Financial Planning Inc. acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $31,000. Logan Capital Management Inc. purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter valued at approximately $61,000. Finally, Ancora Advisors LLC lifted its holdings in Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.